Clinical application of the RONNA G4 system – preliminary validation of 23 robotic frameless brain biopsies

Aims To report the outcomes of robot-assisted brain biopsies performed using a novel RONNA G4 system. The system was developed by a research group from the Faculty of Mechanical Engineering and Naval Architecture and a team of neurosurgeons from Dubrava University Hospital, University of Zagreb School of Medicine.

Methods This prospective study included 49 biopsies analyzed during one year: 23 robotic frameless and 26 frame-based Leksell stereotactic biopsies. We analyzed the presenting symptoms, tumor range and location, postoperative complications, pathohistological diagnosis, diagnostic yield, as well as operation and hospitalization duration. The target point error was calculated to assess the accuracy of the RONNA system.

Results No postoperative mortality, morbidity, or infections were observed. In the frameless robotic biopsy group, only one pathohistological diagnosis was inconclusive. Therefore, the diagnostic yield was 95.6% (22/23), similar to that of the frame-based Leksell stereotactic biopsy group (95.1% or 25/26). The average target point error in the frameless robotic biopsy group was 2.15 ± 1.22 mm (range 0.39-5.85).

Conclusion The RONNA G4 robotic system is a safe and accurate tool for brain biopsy, although further research warrants a larger patient sample, comparison with other robotic systems, and a systematic analysis of the entry and target point errors.
Neurosurgery is one of the most demanding branches of medicine given the need for precision and limitations related to the anatomical area of interest and activity. Since the brain is a specific symmetrical organ enclosed in bone armor, precise localization of a target point within the skull is often challenging. Sophisticated technological innovations in neurosurgery, such as automated robot-assisted systems, offer a unique combination of precision, spatial accuracy, and dexterity. Several decades ago, the introduction of stereotactic frame into neurosurgery (1) established new standards in targeting and localization accuracy. The stereotactic frame is still widely used for brain biopsy procedures (2). The first robotic system used in neurosurgery was industrial robot PUMA 200 (3), after which a number of robotic systems have been developed (4-9). In comparison with humans, robotic systems have increased surgical accuracy, stability, non-fatigue, steadiness and endurance, accurate spatial positioning, quantitative analysis, extension of the visual and manual dexterity of neurosurgeons etc. Possible disadvantages include an inability to handle unexpected situations and required manual labor (10-12). Robotic systems are used in several neurosurgical procedures requiring exceptional spatial accuracy such as stereotactic biopsy, deep brain stimulation (DBS), stereoecephalography, external ventricular drainage, and endoscopy (6-8,13,14). Here, we present a new robotic neuronavigation system RONNA G4 developed by a research group from the Faculty of Mechanical Engineering and Naval Architecture, University of Zagreb, and a team of neurosurgeons from Dubrava University Hospital and the University of Zagreb School of Medicine (15-18). Active research and development within the RONNA project started in 2010 (Figure 1) with an aim to create more precise and intuitive stereotactic neuronavigation procedures. The RONNA system has four generations. In the first generation, we developed a prototype localization device with a precisely calibrated camera and a laser triangulation sensor for the localization of a polymer reference localization marker (18). In 2012, the first-generation system was used in preclinical trials on phantoms. The second-generation system was a refined version of the first generation. As the master (navigation) robot we used KUKA Agilus KR6R900 sixx (16), which is still used in the fourth generation of the RONNA system. The mechanical pose repeatability of the
Kuka Agilus KR6 R900 sixx robot arm with respect to the ISO 9283 is ±0.03 mm. In comparison, the mechanical accuracy of the ROSA system is ±0.1 mm (19).

On the second-generation localization marker, we developed a novel stereovision system for a precise localization of the spherical fiducials (20). The third-generation system,

**FIGURE 2.** RONNA G4 surgical workflow. Before operation, the bone-attached screws are fixed to the patient’s head under local anestheisa (A). The patient undergoes a contrast-enhanced preoperative computed tomography and magnetic resonance imaging according to a standard head protocol (B,C). In the preparation phase, the robot is positioned in an optimal position near the patient. An optical tracking system is used to coarsely position the robot with respect to the patient (D). The trajectory is visualized using a non-sterile probe (E). In the operation phase, after anesthesia induction, the operating field is prepared, and a sterile cover is put on the patient and the robot (F). Using the RONNAplan, the neurosurgeon selects the preoperatively planned trajectory following the tool guide positioning by the robot. Skin incision and burr hole drilling are performed manually by the neurosurgeon (G). A biopsy needle is advanced manually by the neurosurgeon to the target point in order to obtain the tissue for pathohistological analysis (H, I).
The RONNA G4, is currently in the clinical trial phase, and numerous laboratory tests and extensive preclinical trials were performed before clinical application (15,16,21).

The clinical procedure, ie RONNA G4 workflow is performed in three stages (Figure 2). The procedure starts with the preoperative phase. Specially developed self-drilling and self-tapping screws are attached to the cranial bone under local anesthesia to allow precise localization and navigation. For frameless robotic system biopsies, screws are inserted percutaneously while the patient lies comfortably in his or her bed. In contrast, frame mounting requires a forced sitting position and patient’s collaboration to keep his or her head still. Feeling the frame tightening around the head may cause considerable discomfort to the patient. In addition, the frame is carried until the end of biopsy, while the percutaneous screws mostly cannot be seen or felt. Several articles (22,23) report on better tolerance of percutaneous screw placement in patients undergoing frameless robotic system biopsies, supporting our protocol (22,23).

After screw placement, the patient undergoes contrast-enhanced preoperative computed tomography (CT) imaging (Somatom Emotion®, Siemens, Erlangen, Germany) according to our standard head protocol with the following parameters: gantry rotation time 0.6 s, helical scanning, detector collimation 16 mm x0.6 mm, slice-width 0.75 mm, reconstruction increment 0.7 mm, image matrix 512 x512 with a voxel size of 0.5 mm x0.5 mm x0.7 mm, no gantry. After scanning, the images are imported into the operation planning software (RONNAplan) integrated as a plugin for the Osirix MD medical certified software (Pixmeo, Sa’rl, Switzerland). The RONNAplan allows the automatic localization of spherical fiducial markers using our novel algorithm, as previously described (24). The software is non-hardware dependent and can be used as a plugin on any computer running Osirix MD. This allows the neurosurgeon to plan the operative trajectories in a decentralized fashion even a day before the surgical procedure, without the need for a special planning station, making the planning system scalable (Figure 2A-C). The final operative plan is transferred to the RONNA G4 control computer, where it is used for navigation in the operating theater.

The first phase is followed by a preparation phase. After positioning the patient in the operating theater, our novel robot positioning algorithm (25) calculates the optimal position of the robot with respect to the patient. The medical staff manually positions the robot base given the feedback from the global optical tracking system and visual instructions from the RONNAplan software module (Figure 2 D,E).

In the operation phase, after anesthesia induction, the operating field is prepared, and the patient and the robot are covered with a sterile draping. Using the RONNAplan, the neurosurgeon selects the preoperatively planned trajectory following the tool guide positioning by the robot. We developed an intuitive human-robot software interface for controlling intraoperative robot actions. The robot can be easily navigated and positioned in multiple positions, such as the main biopsy position, multiple staged-biopsy positions, drilling position, etc, and be adjusted to different depths of the same trajectory. In the current phase of the clinical trials, the system is used for brain-tissue biopsies. The robot uses a sterile tool holder for a twist drill and a biopsy needle (diameters: 3.2 mm and 2.5 mm, respectively). Skin incision and burr hole drilling are performed manually by the neurosurgeon. After the opening and electrocoagulation of the dura, a biopsy needle (diameter 2.5 mm) is advanced manually by the neurosurgeon to the target point. If needed, the neurosurgeon commands the robot a few millimeters deeper and/or superficial with respect to the target point to perform a staged biopsy. When the biopsy is completed at the target point, the robot retracts to its home position or repositions the tool guide at another target if multiple biopsy sites are planned (Figure 2 F-I).

The aim of our study was to assess efficacy and safety of robotic frameless and stereotactic framebased biopsies.

PATIENTS AND METHODS

This prospective study involved two patient groups. In the first group, the brain biopsies were performed with the RONNA G4 robotic system, and in second group with a framebased stereotactic approach with a
Leksell frame (Elekta AB, Stockholm, Sweden). No clinical or other criteria make a patient more eligible for robotic or stereotactic brain biopsy. Both procedures have the same indications; stereotactic biopsy should be performed whenever open surgery with at least bulk resection is not feasible or when the lesion requires only oncological treatment (26,27). Since our research group is actively developing the RONNA system for robotic frameless brain biopsies, we performed robotic biopsies whenever possible. Frame-based Leksell stereotactic biopsies were performed on all occasions when any part of the robotic system underwent regular maintenance and upgrade, or when an engineer was not available (the engineer presence was preferred in the first stages of development and clinical usage until the system reliability was shown and a learning curve was established). For example, when the robotic system was unavailable due to a software upgrade during a three-month period, we performed only frame-based Leksell stereotactic biopsies. From February 2019 till February 2020, we performed 49 biopsies: 23 robotic and 26 frame-based Leksell stereotactic biopsies. Every patient was informed about the biopsy type and the procedure details. Only one patient refused to participate; the patient was psychoorganically changed due to the tumor extent and localization. The included patients underwent full both preoperative and postoperative neuroradiological examinations (MSCT and MRI) used for additional analysis. All patients or their family members signed informed consent. The ethical approval was obtained from the Institutional Review Boards of Dubrava University Hospital and the University of Zagreb School of Medicine.

RESULTS

The robotic frameless brain biopsy group consisted of 23 patients (7 women), and the frame-based Leksell stereotactic brain biopsy group consisted of 26 patients (12 women). In the frameless robotic biopsy group, the mean age of female patients was 64 ± 15.65 years (range 42-82 years), while that of the male patients was 56 ± 14.41 years (range 28-79 years). In frame-based Leksell biopsy group, the mean age of female patients was 60 ± 10.10 years (range 50-80 years), while that of the male patients was 59.5 ± 15.09 years (range 24-79 years). None of the enrolled patients experienced postoperative mortality, morbidity, or infections. Presenting symptoms, tumor range, postoperative complications, and lesion locations, were similar in both groups (Table 1), stressing possible changes in patients’ presentation (Table 2). In the frameless robotic biopsy group, only one pathological diagnosis was inconclusive, with the diagnostic yield of 95.6% (22/23), similar to the frame-based Leksell stereotactic biopsy group (96.1% or 25/26) (Figure 3). To calculate the target point error (TPE) and to quantify the accuracy of the RONNA system, we used a multimodal rigid body registration algorithm to register the postoperative MRI scan with the preoperative CT scan. TPE was measured on the registered MRI scan at visible deformations that were closest to the target point within the brain or the tumor.

| TABLE 1. Clinical characteristics of the included patients |
|-----------------------------------------------------------|
| Presenting symptoms                                      |
| motor (hemiparesis/monoparesis)                          |
| vertigo/ataxia                                            |
| symptomatic epileptic seizures                            |
| headache                                                  |
| dysphasia                                                 |
| altered behavior                                          |
| asymptomatic, regular control MRI                         |
| Tumor size (mm)                                           |
| ≤30                                                       |
| 30-50                                                     |
| ≥50                                                       |
| multicentric                                             |
| Complications                                             |
| intracerebral hemorrhage                                  |
| neurological worsening                                    |
| pneumocephalus                                            |

|                  | Robotic frameless biopsy | Classic stereotactic biopsy |
|------------------|--------------------------|-----------------------------|
|                  | female (n = 7)          | male (n = 16)               | all (n = 23)                  |
| Presenting symptoms | 1/0         | 4/3             | 8 (5/3)                     |
| Presenting symptoms | 1/1         | 4/0             | 5/1                         |
| motor (hemiparesis/monoparesis)                          | 2/2         | 4 (2/2)        |
| vertigo/ataxia                                            | 1            | 4              |
| symptomatic epileptic seizures                            | 2            | 2              |
| headache                                                  | 2            | 2              |
| dysphasia                                                 | 2            | 2              |
| altered behavior                                          | 9            | 9              |
| asymptomatic, regular control MRI                         | 2            | 2              |
| Tumor size (mm)                                           | 3            | 7              |
| ≤30                                                       | 3            | 6              |
| 30-50                                                     | 1            | 5              |
| ≥50                                                       | 2            | 2              |
| multicentric                                             | 1            | 1              |
| Complications                                             | 1            | 1              |
| intracerebral hemorrhage                                  | -            | -              |
| neurological worsening                                    | -            | -              |
| pneumocephalus                                            | 1            | 2              |
The distance from the planned trajectory and the postoperative defect on the MRI was calculated as a Euclidian distance, which gave the lateral error of the brain biopsy procedure (Figure 4). The average TPE in group I was 2.15 ± 1.22 (range 0.39-5.85) (Figure 4). Additionally, the duration of the operation, i.e., the time from the moment the patient entered the operating theater until the operative procedure ended was 69.3 ± 20.3 min (range 41-128 min) in the frameless robotic biopsy group, and 38 ± 12.28 (range 21-57 min) in the framebased Leksell stereotactic biopsy group. The average hospital stay was 4.57 ± 1.08 days (range 3-6 days) in the frameless robotic biopsy group, and 6.5 ± 0.67 days (range 2-30 days) in the framebased Leksell stereotactic biopsy group. In the robotic frameless system group, complications occurred in three patients. One patient with a parietooccipital tumor, size 30 mm, experienced intracerebral hemorrhage without neurological worsening. Two patients experienced pneumocephalus, one with a frontal tumor size of 30-50 mm, without neurological worsening, and the other with a temporal tumor size of 30-50 mm, also without neurological worsening.

**DISCUSSION**

The current study showed no difference in the efficacy, diagnostic yield, and complications between frameless robotic and framebased Leksell stereotactic biopsy systems.

Surgical robotics is one of the most significant technological advances in neurosurgery. The fourth-generation RONNA has multiple new unique software and hardware features compared with other commercial or experimental robotic neuronavigation systems (4,5,28,29). The main feature are the freely distributed fiducial mark-

**TABLE 2.** The locations of pathohistological samples

| Location          | Robotic frameless biopsy | Classic stereotactic biopsy |
|-------------------|--------------------------|----------------------------|
|                   | female (n = 7) | male (n = 16) | all (n = 23) | female (n = 12) | male (n = 14) | all (n = 26) |
| Thalamus          | 1              | 4              | 5            | 1              | 1              | 2            |
| Temporal lobe     | 1              | 4              | 5            | 2              | 3              | 5            |
| Insula            | 1              | 1              | 1            | 1              | 1              | 1            |
| Parietal lobe     | 2              | 2              | 2            | 2              | 3              | 5            |
| Occipital lobe    | 2              | 2              | 5            | 1              | 1              | 1            |
| Cerebellum        | 1              | 1              | 1            | 1              | 1              | 1            |
| Frontal lobe      | 2              | 4              | 6            | 2              | 3              | 5            |
| Brainstem         | 1              | 1              | 1            | 1              | 1              | 1            |
| Corpus callosum   | 1              | 1              | 1            | 1              | 1              | 1            |
| Basal ganglia     | 1              | 1              | 1            | 1              | 1              | 1            |

**FIGURE 3.** Results of the pathohistological analysis for the tumor tissue obtained using the RONNA G4 frameless brain biopsy and framebased stereotactic brain biopsy.
ers, ie, bone fiducials, which consist of a bone screw and a special screw cap with interchangeable spherical re-troreflective fiducials. The RONNA G4 bone screw set consists of a milled aluminum instrument tray holding eight screws and eight screw caps, and a specially designed screwdriver (Eonex Medical, Trnovec, Croatia) (Figure 5).

The whole set is sterilized before surgery in the autoclave. To minimize the effect of metallic artifacts in CT images, the screw caps are made of polyether ether ketone, a medical-grade polymer. The screw caps have a mechanical interface for standard medical retroreflec-tive snap-fit spherical markers (NDI – Northern Digital Inc., Waterloo, Canada). When it comes to software features, RONNA G4 uses a new and improved algorithm for

---

**FIGURE 4.** The methodology used for target point error measurement; tissue defect of tumor sampling site superimposed with a preoperative plan (A). A range of measured target point error values presented a mean ± standard deviation (B).

**FIGURE 5.** The RONNA bone screw set consisting of a milled aluminum instrument tray that holds eight screws, eight screw caps, and a specially designed screwdriver.

**FIGURE 6.** Trajectory cross-section of an inconclusive frameless robotic biopsy presenting target point on the tumor margin.
autonomous localization of fiducial markers in the image space (24), an algorithm for robot position planning with respect to the patient in the physical space (25), a novel pair-point correspondence algorithm for the patient registration from the image space to the physical space (30), and a novel method for determining an optimal robot localization strategy in the physical space (31). Other major features that differentiate the RONNA G4 from the current state-of-the-art robotic neuronavigation systems are a specifically designed universal mobile platform (32) and a new and accurate non-contact localization system (18). The universal mobile platform can be used for different robot arms and is not limited to a unique robot model. The high-precision non-contact localization system RONNAstereo is used for accurate patient localization in the image space. For safety reasons, RONNA G4 has an uninterruptible power supply and 20-minute autonomy in case of power failure. It is also equipped with numerous built-in software and hardware safety measures. A speed limiter is used for all linear and joint movements to limit speeds to 30 mm/s or 5°/s. An emergency stop button (manual shutoff button) is incorporated both as a hardware and software option. All robot motions are planned before the execution, and collisions between the robot, its tools, and the patient are continuously checked.

Conventional frame-based procedures still represent the gold standard for brain biopsies. Although stereotactic frames such as Leksell, Cosman-Brown-Wells (Integra, Mayfield Cranial Stabilization System, Plainsboro, NJ, USA), and/or other frames are widely used (2), frameless biopsy has several advantages over stereotactic frame-based biopsies. One of the main advantages is less patient discomfort. Furthermore, frameless biopsies allow making preoperative scans a day before surgery, enabling a more flexible planning strategy. More time is available for a detailed operative plan analysis, allowing the planning of better trajectories. An advantage of the RONNA G4 robotic neuronavigation system and a head holder (such as a Mayfield clamp – Integra, Mayfield Cranial Stabilization System) in a frameless setup allows the creation of both lateral and posterior trajectories without hardware limitations, which is not the case in frame-based biopsies (17). In addition, frameless systems allow multiple trajectory planning and switching between trajectories within seconds, thus simplifying and speeding-up the procedure for multiple biopsy locations.

Several points should be discussed when comparing our study with previously published frame-based, frameless, and robotic biopsy studies (2,5,28,29,33). In other studies, the sample size varied from fewer than ten to more than 200 patients. Thus, we believe our preliminary results from a sample of 23 patients to be valid, considerable, and comparable with other studies in the field of stereotactic brain biopsies. In frame-based and frameless biopsy studies, the mortality ranged from around 1% to 4% and morbidity from 1% to more than 20%, and in robotic brain biopsies the mortality and morbidity rates were less than 10%. In our study, no postoperative mortality or morbidity were observed. Complications included intracerebral hemorrhage in only one patient and pneumocephalus in two patients, visible on postoperative CT and/or MRI scan, without neurological worsening. In the available frame-based and frameless biopsy studies, both hemorrhage and neurological deficit occurred in 1% to 20% of patients. In robotic brain biopsies, hemorrhage and neurological deficit occurred in approximately 4% to 28% of patients. The average procedure time ranges from $56.3 \pm 23.6$ to $185 \pm 6$ min for frameless biopsy studies and $54.2 \pm 31.9$ to $149 \pm 32$ min for frame-based studies, while the average operation duration in our study was $71 \pm 20.7$ min. Still, we believe that the average procedure time will shorten as neurosurgeons become more experienced. The diagnostic yield in our sample was 95.6% (22/23). In the literature, the diagnostic yield for various frameless biopsy cohorts ranged from 86.6% to 100%, for frame-based biopsy cohorts it ranged from 84% to 100%, and for robotic brain biopsies it ranged from 75% to 100% (2,5,28,29,33).

The single inconclusive sample was located at the level of the crura cerebri and mesencephalon. Usually, tissue samples obtained during brain biopsies are not sent for intraoperative pathohistological diagnosis. The reasons are short operation duration, a few small tissue samples obtained during biopsy (tissue cylinder), and the time needed to perform intraoperative pathological analysis. Tissue sampling during biopsy may lead to malignant tumor bleeding causing intracerebral hemorrhage in 5% to more than 20% of the cases (34). Thus, to avoid possible complications when performing deep-seated brain tumor biopsies with neuroradiological signs of malignancies, especially at the level of the crura cerebri as was the case in this patient, the target for tissue sampling is set on the tumor margin. We repeated the biopsy with Leksell frame; the pathohistological diagnosis was glioblastoma, and the patient underwent oncological treatment. On the repeated biopsy, based on our previous experience, we planned a riskier target point in the middle of the tumor since pathohistological diagnosis was mandatory for oncological treatment, which was the only treatment option for the patient (26,27). In addition, postoperative MRI did not
show mistargeting (Figure 6). The obtained tissue was the tumor-surrounding tissue, as we planned due to the above mentioned reasons. In addition, several factors, such as high coronal trajectory angle, a long trajectory, and especially minimal bending of the biopsy probe due to passing through the sulci, ie, tissues of different resistance, as well as the planned marginal area contributed to an unsuccessful pathohistological diagnosis.

Thus, the obtained RONNA G4 diagnostic yield values are comparable and higher than the average diagnostic yield in other studies (2,5,28,29,33). One of the challenges to the widespread acceptance of robotics in neurosurgery is the ability to train neurosurgeons to use these new technologies. An increase in neurosurgeon’s experience over time is associated with shorter procedure duration, length of postoperative hospitalization, and the incidence of complications. In neurosurgery, technical advancements will continue to improve the speed, accuracy, and tactile ability in computer-assisted surgeries. Completely autonomous neurosurgical procedures are still a long way off, but robotics is already progressively changing the face of neurosurgery.

Our results should be interpreted with several limitations in mind. First, the number of participants is relatively small, and the results need to be confirmed in a larger cohort. In addition, an in-depth accuracy system analysis with included errors of measurement should be conducted, as was previously described in the literature (2,4,5,8,22). All other factors that considerably affect the accuracy and diagnostic yield should be investigated, and in vitro studies should be conducted (35). Different planning software programs and platforms prevented us from comparing the accuracy measurement between robotic frameless and framebased Leksell stereotactic biopsies.

In conclusion, the RONNA G4 robotic system is a safe and accurate tool for performing brain biopsy. Further studies need to enroll a larger patient sample for comparison with other robotic systems, to systematically analyze the entry and target point errors, and to investigate a wider application of robotic systems (DBS, SEEG, catheter placement). As the research on robotic brain biopsies is limited, our prospective study adds to the knowledge on robotic stereotactic brain biopsies. We plan to perform more detailed studies on robotic frameless and framebased Leksell stereotactic biopsies and their application accuracy.

Funding This research was supported by the Adris Foundation Grant “Application Analysis of a Robotic System for Stereotactic Neuronavigation” to DC.

Ethical approval given the Institutional Review Boards of Dubrava University Hospital and the Zagreb University School of Medicine (641:01/13-02).

Declaration of authorship DD, MŠ, and MR conceived and designed the study; DC, BJ, BŠ, FŠ, JV, FA, and DR acquired the data; DD, MŠ, and MR analyzed and interpreted the data; DD, MŠ, and MR drafted the manuscript; DC, BJ, BŠ, FŠ, JV, FA, and DR critically revised the manuscript for important intellectual content; all authors gave approval of the version to be submitted; all authors agree to be accountable for all aspects of the work.

Competing interests All authors have completed the Unified Competing Interest form at www.icmje.org/coiDisclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

References
1 Spiegel EA, Wycis HT, Marks M, Lee AJ. Stereotactic apparatus for operations on the human brain. Science. 1947;106(2754):349-50.
2 Dhawan S, He Y, Bartek J, Alattar AA, Chen CC. Comparison of frame-based versus frameless intracranial stereotactic biopsy: systematic review and meta-analysis. World Neurosurg. 2019;127:607-616.e4. Medline:30974279 doi:10.1016/j.wneu.2019.04.016
3 Kwoh YS, Hou J, Jonckheere EA, Hayati S. A robot with improved absolute po-sitioning accuracy for CT guided stereotactic brain surgery. IEEE Trans Biomed Eng. 1988;35:153-60. Medline:3280462 doi:10.1109/10.1354
4 Fomenko A, Serletis D. Robotic stereotaxy in cranial neurosurgery: a qualitative systematic review. Neurosurgery. 2018;83:642-50. Medline:29253265 doi:10.1093/neuros/nyx576
5 Marcus HJ, Vakharia VN, Ourselin S, Duncan J, Tisdall M, Aquilina K. Robot-assisted stereotactic brain biopsy: systematic review and bibliometric analysis. Childs Nerv Syst. 2018;34:1299-309. Medline:29744625 doi:10.1007/s00381-018-3821-y
6 Cardinale F, Cossu M, Castana L, Cascagi S, Schiari MP, Misereocchi A, et al. Stereoelectroencephalography: Surgical Methodology, Safety, and Stereotactic Application Accuracy in 500 Procedures. Neurosurgery. 2013;72:353-66. Medline:23168681 doi:10.1227/ NEU.0b013e31827d1161
7 González-Martínez J, Bulacio J, Thompson S, Gale J, Smithason S, Najm I, et al. technique, results, and complications related to robot-assisted stereoelectroencephalography. Neurosurgery. 2016;78:169-80. Medline:26418870 doi:10.1227/NEU.0000000000001034
8 Minchev G, Kronref G, Martínez-Moreno M, Dorfer C, Micko A, Mert A, et al. A novel miniature robotic guidance device for stereotactic neurosurgical interventions: preliminary experience with the iSYS1 Robot. J Neurosurg. 2016;126:985-96. Medline:27104847 doi:10.1234/jneuros.2016.1.1.NS152005
9 Lefranc M, Le Gars D. Robotic implantation of deep brain stimulation leads, assisted by intra-operative, flat-panel CT. Acta Neurochir (Wien). 2012;154:2069-74. Medline:22814648 doi:10.1007/s00701-012-1445-7
10 Eljamel MS. Validation of the PathfinderTM neurosurgical robot using a phantom. Int J Med Robot. 2007;3:372-7. Medline:17914750

www.cmj.hr
Dlaka et al: Clinical application of the RONNA G4 system

frame-based stereotaxy: prospective, randomized, single-center study. World Neurosurg. 2017;104:831-40. Medline:28454992 doi:10.1016/j.wneu.2017.04.104

23 Wu S, Wang J, Gao P, Liu W, Hu F, Jiang W, et al. A comparison of the efficacy, safety, and duration of frame-based and Remebot robot-assisted frameless stereotactic biopsy. Br J Neurosurg. 2020;17:1-5. Medline:32940070 doi:10.1080/02688697.2020.1812519

24 Šuligoj F, Švaco M, Jerbić B, Šekoranja B, Vidaković J. Automated marker localization in the planning phase of robotic neurosurgery. IEEE Access. 2017;5:12265-74. doi:10.1109/ACCESS.2017.2718621

25 Vidaković J, Jerbić B, Švaco M, Šuligoj F, Šekoranja B. Position planning for collaborating robots and its application in neurosurgery. Tehnicki vjesnik - Technical Gazette. 2017;24(6).

26 Bosch DA. Indications for stereotactic biopsy in brain tumours. Acta Neurochir (Wien). 1980;54:167-79. Medline:7004105 doi:10.1007/BF01407083

27 Fedden W, Biše K, Steude U. Diagnosis of primary cerebral lymphoma with particular reference to CT-guided stereotactic biopsy. Virchows Arch A Pathol Anat Histopathol. 1990;417:21-8. Medline:2113737 doi:10.1007/BF01600105

28 Brandmeir NJ, Savailya S, Rohatgi P, Sather M. The comparative accuracy of the ROSA stereotactic robot across a wide range of clinical applications and registration techniques. J Robot Surg. 2018;12:157-63. Medline:28484885 doi:10.1007/s11701-017-0712-2

29 Yasin H, Hoff HJ, Blümcke I, Simon M. Experience with 102 frameless stereotactic biopsies using the neuronate robotic device. World Neurosurg. 2019;123:e450-6. Medline:30500594 doi:10.1016/j.wneu.2018.11.187

30 Šuligoj F, Jerbić B, Švaco M, Šekoranja B. Fully Automated point-based robotic neurosurgical patient registration procedure. Int J Simul Model. 2018;17:458-71. doi:10.1057/JSIMM14(1)17.290

31 Šuligoj F, Jerbić B, Švaco M, Šekoranja B. Automated point-based robotic neuronavigation system. Trans FAMeNA. 2018;42:27-38. doi:10.21278/TOF.4220

32 Švaco M, Šekoranja B, Šuligoj F, Vidaković J, Jerbić B. Influence of the localization strategy on the accuracy of a neurosurgical robot system. Trans FAMENA. 2018;42:27-38. doi:10.21278/TOF.4220

33 Švaco M, Šekoranja B, Šuligoj F, Vidaković J, Jerbić B, Chudy D. A Novel Robotic Neuronavigation System: RONNA G3. Strojniški vjesnik. 2017;63:725-35.

34 Takanishi G, Ohata T, Fujita T, Kato Y, Kato K, Kato K, et al. The accuracy of the ROSA stereotactic robot across a wide range of clinical applications and registration techniques. J Robot Surg. 2018;12:157-63. Medline:28484885 doi:10.1007/s11701-017-0712-2

35 Šuligoj F, Jerbić B, Švaco M, Šekoranja B. Fully Automated point-based robotic neurosurgical patient registration procedure. Int J Simul Model. 2018;17:458-71. doi:10.1057/JSIMM14(1)17.290

36 Šuligoj F, Jerbić B, Švaco M, Šekoranja B. Fully Automated point-based robotic neurosurgical patient registration procedure. Int J Simul Model. 2018;17:458-71. doi:10.1057/JSIMM14(1)17.290

37 Švaco M, Šekoranja B, Šuligoj F, Vidaković J, Jerbić B, Chudy D. A Novel Robotic Neuronavigation System: RONNA G3. Strojniški vjesnik - Tehnicki vjesnik. 2017;63:725-35.

38 Terrier L, Gilard V, Marguet F, Fontanillers M, Derrey S. Stereotactic brain biopsy: evaluation of robot-assisted procedure in 60 patients. Acta Neurochir (Wien). 2019;161:545-52. Medline:30675655 doi:10.1007/s00701-018-3808-5

39 Mizobuchi Y, Nakajima K, Fujihara T, Matsuzaki K, Mure H, Nagahiro S, Takagi Y. The risk of hemorrhage in stereotactic biopsy for brain tumors. J Med Invest. 2019;66(3-4):314-318.

40 Švaco M, Stiperski I, Dlaka D, Šuligoj F, Jerbić B, Chudy D, et al. Stereotactic neuronavigation phantom designs: a systematic review. Front Neurorobot. 2020. Medline:33192433